A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation

[1]  I. Yakoub-Agha,et al.  Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. , 2008, Blood.

[2]  B. Barlogie,et al.  High‐dose melphalan‐based autotransplants for multiple myeloma , 2008, Cancer.

[3]  W. Bensinger.  Stem-cell transplantation for multiple myeloma in the era of novel drugs. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Zhan,et al.  Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling , 2007, Clinical Cancer Research.

[5]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[6]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[7]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[8]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[9]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[10]  V. Rajkumar,et al.  Multiple myeloma: the death of VAD as initial therapy , 2005 .

[11]  M. Kubota,et al.  Maintenance with Pamidronate Following First-line MP or VAD Therapy in Multiple Myeloma , 2003, Leukemia & lymphoma.

[12]  B. Barlogie,et al.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma , 2002, British journal of haematology.

[13]  H. Garewal,et al.  Aggressive phase of multiple myeloma with pulmonary cell infiltrates. , 1982, JAMA.

[14]  A. Suchman,et al.  Aggressive plasma cell myeloma. A terminal phase. , 1981, Archives of internal medicine.

[15]  P. Sonneveld,et al.  Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.

[16]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[17]  S. Allen,et al.  Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma. , 1990, Cancer investigation.

[18]  Y. Shoenfeld,et al.  Aggressive plasma cell myeloma. , 1982, Acta haematologica.